Reed Elsevier

Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has climbed more than 500% over the last decade.

But the drugmaker didn't budge on its price, which has drawn ire both in Congress and from families that have had to shell out increasingly large sums for the potentially life-saving treatment.

That means the insurers and employers that pay the bulk of the EpiPen cost for many patients will continue to do so, contributing to higher health insurance costs.

“That's just going to come out in the premiums,” said Sabrina Corlette, a research professor at...

Related "Reed Elsevier" Articles

Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has climbed more than 500% over the last decade.
But the drugmaker didn't budge on its price,...

The journal Food and Chemical Toxicology is retracting a highly controversial French study it published last year linking genetically modified maize to cancerous tumors in rats.
In a statement released from its Cambridge, Mass., offices on Thursday,...